A detailed history of Advisor Group Holdings, Inc. transactions in Spero Therapeutics, Inc. stock. As of the latest transaction made, Advisor Group Holdings, Inc. holds 295 shares of SPRO stock, worth $348. This represents 0.0% of its overall portfolio holdings.

Number of Shares
295
Previous 295 -0.0%
Holding current value
$348
Previous $0 NaN%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$1.27 - $1.8 $314 - $446
248 Added 527.66%
295 $0
Q1 2024

May 10, 2024

SELL
$1.35 - $1.79 $67 - $89
-50 Reduced 51.55%
47 $0
Q3 2023

Nov 13, 2023

SELL
$1.2 - $1.63 $2,510 - $3,409
-2,092 Reduced 95.57%
97 $0
Q2 2023

Aug 10, 2023

SELL
$1.42 - $1.95 $1,327 - $1,823
-935 Reduced 29.93%
2,189 $3,000
Q1 2023

May 12, 2023

BUY
$1.35 - $2.0 $63 - $94
47 Added 1.53%
3,124 $4,000
Q4 2022

Feb 10, 2023

SELL
$1.55 - $2.12 $33,697 - $46,088
-21,740 Reduced 87.6%
3,077 $5,000
Q3 2022

Nov 14, 2022

BUY
$0.68 - $2.2 $14,974 - $48,448
22,022 Added 787.91%
24,817 $50,000
Q2 2022

Aug 10, 2022

BUY
$0.74 - $7.44 $1,258 - $12,648
1,700 Added 155.25%
2,795 $2,000
Q1 2022

May 04, 2022

SELL
$7.87 - $15.15 $11,435 - $22,012
-1,453 Reduced 57.03%
1,095 $3.47 Million
Q3 2021

Nov 05, 2021

SELL
$13.03 - $19.51 $97,920 - $146,617
-7,515 Reduced 74.68%
2,548 $46,000
Q2 2021

Aug 02, 2021

SELL
$12.22 - $15.79 $392,873 - $507,648
-32,150 Reduced 76.16%
10,063 $143,000
Q1 2021

May 13, 2021

BUY
$13.23 - $21.48 $389,517 - $632,414
29,442 Added 230.54%
42,213 $621,000
Q4 2020

Feb 10, 2021

BUY
$11.65 - $22.07 $148,782 - $281,855
12,771 New
12,771 $248,000

Others Institutions Holding SPRO

About Spero Therapeutics, Inc.


  • Ticker SPRO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 35,067,500
  • Market Cap $41.4M
  • Description
  • Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to ...
More about SPRO
Track This Portfolio

Track Advisor Group Holdings, Inc. Portfolio

Follow Advisor Group Holdings, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Advisor Group Holdings, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Advisor Group Holdings, Inc. with notifications on news.